AAAAAA

   
Results: 1-18 |
Results: 18
RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND-STUDY OF A CMV GLYCOPROTEIN H-SPECIFIC MONOCLONAL-ANTIBODY (MSL-109) FOR PREVENTION OF CMV INFECTION AFTER ALLOGENEIC HEMATOPOIETIC STEM-CELL TRANSPLANT (HSCT)
Authors: BOECKH M BOWDEN RA CHAO NJ STORER B SPIELBERGER R TIERNEY DK HAWKINS G CUNNINGHAM T LEVITT D ZAIA JA
Citation: M. Boeckh et al., RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND-STUDY OF A CMV GLYCOPROTEIN H-SPECIFIC MONOCLONAL-ANTIBODY (MSL-109) FOR PREVENTION OF CMV INFECTION AFTER ALLOGENEIC HEMATOPOIETIC STEM-CELL TRANSPLANT (HSCT), Bone marrow transplantation, 21, 1998, pp. 477-477
ALLOGENEIC (ALLO) AND MATCHED UNRELATED DONOR (MUD) BONE-MARROW TRANSPLANTATION (BMT) IN 46 PATIENTS GREATER-THAN 50 YEARS OF AGE
Authors: KASHYAP A PARKER P NADEMANEE A FUNG H MOLINA A BHATIA R KRISHNAN A ODONNELL MR PLANAS I SNYDER DS SPIELBERGER R STEIN A LEE J FORMAN SJ
Citation: A. Kashyap et al., ALLOGENEIC (ALLO) AND MATCHED UNRELATED DONOR (MUD) BONE-MARROW TRANSPLANTATION (BMT) IN 46 PATIENTS GREATER-THAN 50 YEARS OF AGE, Blood, 90(10), 1997, pp. 468-468
HIGH-DOSE THERAPY AND AUTOLOGOUS STEM TRANSPLANTATION (ASCT) AS CONSOLIDATION THERAPY DURING FIRST COMPLETE REMISSION (CR) OR PARTIAL REMISSION (PR) IN PATIENTS WITH UNFAVORABLE PROGNOSIS AND ADVANCED-STAGE HODGKINS-DISEASE (HD)
Authors: NADEMANEE A MOLINA A STEIN A PLANAS I FUNG H DAGIS A ODONNELL MR SNYDER DS PARKER P SPIELBERGER R KASHYAP A BHATIA R KRISHNAN A SNIECINSKI K VORA N FORMAN SJ
Citation: A. Nademanee et al., HIGH-DOSE THERAPY AND AUTOLOGOUS STEM TRANSPLANTATION (ASCT) AS CONSOLIDATION THERAPY DURING FIRST COMPLETE REMISSION (CR) OR PARTIAL REMISSION (PR) IN PATIENTS WITH UNFAVORABLE PROGNOSIS AND ADVANCED-STAGE HODGKINS-DISEASE (HD), Blood, 90(10), 1997, pp. 495-495
PHASE-2 STUDY OF INTERLEUKIN-2 (IL-2) FOLLOWING AUTOLOGOUS STEM-CELL TRANSPLANT (ASCT) FOR ADULT PATIENTS WITH ACUTE MYELOGENOUS LEUKEMIA (AML) IN FIRST COMPLETE REMISSION (CR)
Authors: STEIN A ODONNELL MR LEE J BHATIA R FUNG H KASHYAP A KRISHNAN A NADEMANEE A MOLINA A MARGOLIN K PARKER P PLANAS I SPIELBERGER R SNYDER D SMITH E SOMLO G SLOVAK ML VORA N SNIECINSKI I NILAND J FORMAN SJ
Citation: A. Stein et al., PHASE-2 STUDY OF INTERLEUKIN-2 (IL-2) FOLLOWING AUTOLOGOUS STEM-CELL TRANSPLANT (ASCT) FOR ADULT PATIENTS WITH ACUTE MYELOGENOUS LEUKEMIA (AML) IN FIRST COMPLETE REMISSION (CR), Blood, 90(10), 1997, pp. 1699-1699
TANDEM CYCLE HIGH-DOSE CHEMOTHERAPY (HDCT) OF MELPHALAN (MEL) AND BUSULFAN CYCLOPHOSPHAMIDE (BU/CY) WITH PERIPHERAL-BLOOD PROGENITOR-CELL RESCUE (PBPC) IN MULTIPLE-MYELOMA (MM)/
Authors: SOMLO G SNYDER D BROWN A DAGIS A NADEMANEE A ODONNELL M PARKER P STEIN A SMITH E MOLINA A SPIELBERGER R MARGOLIN K PLANAS I KASHYAP A CHOW W FUNG H BHATIA R FORMAN SJ
Citation: G. Somlo et al., TANDEM CYCLE HIGH-DOSE CHEMOTHERAPY (HDCT) OF MELPHALAN (MEL) AND BUSULFAN CYCLOPHOSPHAMIDE (BU/CY) WITH PERIPHERAL-BLOOD PROGENITOR-CELL RESCUE (PBPC) IN MULTIPLE-MYELOMA (MM)/, Blood, 90(10), 1997, pp. 1709-1709
EVALUATION OF PROGNOSTIC FACTORS IN PATIENTS (PTS) WITH HODGKIN-DISEASE (HD) IN FIRST RELAPSE (REL) TREATED BY AUTOLOGOUS STEM-CELL TRANSPLANTATION (ASCT) - DURATION OF FIRST REMISSION DOES NOT PREDICT THE TRANSPLANT OUTCOME
Authors: FUNG H NADEMANEE A KASHYAP A MOLINA A ODONNELL M SNYDER D PARKER P STEIN A PLANAS I SPIELBERGER R KRISHNAN A BHATIA R MARGOLIN K SOMLO G CHOW W DAGIS A NILAND J PEZNER R FORMAN SJ
Citation: H. Fung et al., EVALUATION OF PROGNOSTIC FACTORS IN PATIENTS (PTS) WITH HODGKIN-DISEASE (HD) IN FIRST RELAPSE (REL) TREATED BY AUTOLOGOUS STEM-CELL TRANSPLANTATION (ASCT) - DURATION OF FIRST REMISSION DOES NOT PREDICT THE TRANSPLANT OUTCOME, Blood, 90(10), 1997, pp. 2637-2637
RESULTS OF HIGH-DOSE THERAPY AND AUTOLOGOUS BONE-MARROW STEM-CELL TRANSPLANTATION DURING REMISSION IN POOR-RISK INTERMEDIATE-GRADE AND HIGH-GRADE LYMPHOMA - INTERNATIONAL INDEX HIGH AND HIGH-INTERMEDIATE RISK GROUP
Authors: NADEMANEE A MOLINA A ODONNELL MR DAGIS A SNYDER DS PARKER P STEIN A SMITH E PLANAS I KASHYAP A SPIELBERGER R FUNG H WONG KK SOMLO G MARGOLIN K CHOW W SNIECINSKI I VORA N BLUME KG NILAND J FORMAN SJ
Citation: A. Nademanee et al., RESULTS OF HIGH-DOSE THERAPY AND AUTOLOGOUS BONE-MARROW STEM-CELL TRANSPLANTATION DURING REMISSION IN POOR-RISK INTERMEDIATE-GRADE AND HIGH-GRADE LYMPHOMA - INTERNATIONAL INDEX HIGH AND HIGH-INTERMEDIATE RISK GROUP, Blood, 90(10), 1997, pp. 3844-3852
IN-VIVO PURGING WITH HIGH-DOSE CYTARABINE FOLLOWED BY HIGH-DOSE CHEMORADIOTHERAPY AND REINFUSION OF UNPURGED BONE-MARROW FOR ADULT ACUTE MYELOGENOUS LEUKEMIA IN FIRST COMPLETE REMISSION
Authors: STEIN AS ODONNELL MR CHAI A SCHMIDT GM NADEMANEE A PARKER PM SMITH EP SNYDER DS MOLINA A STEPAN DE SPIELBERGER R SOMLO G MARGOLIN KA VORA N LIPSETT J LEE J NILAND J FORMAN SJ
Citation: As. Stein et al., IN-VIVO PURGING WITH HIGH-DOSE CYTARABINE FOLLOWED BY HIGH-DOSE CHEMORADIOTHERAPY AND REINFUSION OF UNPURGED BONE-MARROW FOR ADULT ACUTE MYELOGENOUS LEUKEMIA IN FIRST COMPLETE REMISSION, Journal of clinical oncology, 14(8), 1996, pp. 2206-2216
POLYMYOSITIS AS A MANIFESTATION OF CHRONIC GRAFT-VERSUS-HOST DISEASE
Authors: PARKER P CHAO NJ BENEZRA J SLATKIN N OPENSHAW H NILAND JC LINKER CA GREFFE BS KASHYAP A MOLINA A NADEMANEE A ODONNELL MR PLANAS I SHEIBANI K SMITH EP SNYDER DS SPIELBERGER R STEIN AS STEPAN DE BLUME KG FORMAN SJ
Citation: P. Parker et al., POLYMYOSITIS AS A MANIFESTATION OF CHRONIC GRAFT-VERSUS-HOST DISEASE, Medicine, 75(5), 1996, pp. 279-285
IMPROVED CR RATE USING HIGH-DOSE MELPHALAN (HDM) PRE G-CSF-PRIMED DONOR LEUKOCYTE INFUSION (DLI) FOR 2ND ALLOGENEIC BMT - ACUTE GRAFT-VERSUS-HOST DISEASE (AGVHD) PROPHYLAXIS IS NECESSARY FOR PATIENTS AT RISK FOR HYPERACUTE GVHD
Authors: PARKER PM KASHYAP A SPIELBERGER R SNIECZINSKI I CHOW W FUNG H MARGOLIN K MOLINA A NADEMANEE A ODONNELL M PLANAS I SMITH E SNYDER DS SOMLO G STEIN A FORMAN SJ
Citation: Pm. Parker et al., IMPROVED CR RATE USING HIGH-DOSE MELPHALAN (HDM) PRE G-CSF-PRIMED DONOR LEUKOCYTE INFUSION (DLI) FOR 2ND ALLOGENEIC BMT - ACUTE GRAFT-VERSUS-HOST DISEASE (AGVHD) PROPHYLAXIS IS NECESSARY FOR PATIENTS AT RISK FOR HYPERACUTE GVHD, Blood, 88(10), 1996, pp. 3805-3805
DO CYTOGENETICS PREDICT OUTCOME OF AUTOLOGOUS BONE-MARROW TRANSPLANTATION (ABMT) FOR ACUTE MYELOGENOUS LEUKEMIA (AML) IN 1ST REMISSION (CR)
Authors: STEIN AS ODONNELL MR SLOVAK M LEE J KASHYAP A MOLINA A NADEMANEE A PARKER P PLANAS I SNYDER DS SPIELBERGER R SOMLO G MARGOLIN K NILAND J FORMAN SJ
Citation: As. Stein et al., DO CYTOGENETICS PREDICT OUTCOME OF AUTOLOGOUS BONE-MARROW TRANSPLANTATION (ABMT) FOR ACUTE MYELOGENOUS LEUKEMIA (AML) IN 1ST REMISSION (CR), Blood, 88(10), 1996, pp. 1928-1928
ALLOGENEIC BONE-MARROW TRANSPLANTATION (BMT) IN PATIENTS (PTS) WITH INCURABLE LOW-GRADE LYMPHOPROLIFERATIVE DISORDERS (LGLPD)
Authors: MOLINA A PARKER P STEIN AS SPIELBERGER R NADEMANEE A SNYDER DS ODONNELL MR SMITH EP MARGOLIN K DAGIS A PLANAS I KASHYAP A SOMLO G KAPOOR N VORA N NILAND J FORMAN SJ
Citation: A. Molina et al., ALLOGENEIC BONE-MARROW TRANSPLANTATION (BMT) IN PATIENTS (PTS) WITH INCURABLE LOW-GRADE LYMPHOPROLIFERATIVE DISORDERS (LGLPD), Blood, 88(10), 1996, pp. 2465-2465
HIGH-DOSE THERAPY AND AUTOLOGOUS BONE-MARROW STEM-CELL TRANSPLANTATION (ABMT) AS CONSOLIDATION THERAPY DURING FIRST CR PR IN PATIENTS WITH POOR-RISK INTERMEDIATE-AND HIGH-GRADE LYMPHOMA/
Authors: NADEMANEE A MOLINA A ODONNELL M SNYDER DS STEIN A PARKER P SMITH E KASHYAP A PLANAS I SPIELBERGER R FUNG H SOMLO G MARGOLIN K CHOW W VORA N DAGIS A NILAND J BLUME KG FORMAN SJ
Citation: A. Nademanee et al., HIGH-DOSE THERAPY AND AUTOLOGOUS BONE-MARROW STEM-CELL TRANSPLANTATION (ABMT) AS CONSOLIDATION THERAPY DURING FIRST CR PR IN PATIENTS WITH POOR-RISK INTERMEDIATE-AND HIGH-GRADE LYMPHOMA/, Blood, 88(10), 1996, pp. 2725-2725
THALIDOMIDE AS SALVAGE THERAPY FOR CHRONIC GRAFT-VERSUS-HOST DISEASE
Authors: PARKER PM CHAO N NADEMANEE A ODONNELL MR SCHMIDT GM SNYDER DS STEIN AS SMITH EP MOLINA A STEPAN DE KASHYAP A PLANAS I SPIELBERGER R SOMLO G MARGOLIN K ZWINGENBERGER K WILSMAN K NEGRIN RS LONG GD NILAND JC BLUME KG FORMAN SJ
Citation: Pm. Parker et al., THALIDOMIDE AS SALVAGE THERAPY FOR CHRONIC GRAFT-VERSUS-HOST DISEASE, Blood, 86(9), 1995, pp. 3604-3609
IDARUBICIN (IDA) AND HIGH-DOSE CYTOSINE-ARABINOSIDE (HD ARA-C) FOR INDUCTION THERAPY FOR AML AND AML ARISING FROM MYELODYSPLASIA (MDS AML)/
Authors: STEIN AS ODONNELL MR NADEMANEE A PARKER P LEE J MOLINA A KASHYAP A SPIELBERGER R SMITH E PLANAS I SNYDER D SOMLO G MARGOLIN K NILAND J FORMAN SJ
Citation: As. Stein et al., IDARUBICIN (IDA) AND HIGH-DOSE CYTOSINE-ARABINOSIDE (HD ARA-C) FOR INDUCTION THERAPY FOR AML AND AML ARISING FROM MYELODYSPLASIA (MDS AML)/, Blood, 86(10), 1995, pp. 2046-2046
PILOT-STUDY OF INTERFERON-ALPHA RECEPTOR (IFN-ALPHA-R) EXPRESSION IN PATIENTS WITH CHRONIC MYELOGENOUS LEUKEMIA (CML)
Authors: SPIELBERGER R SNYDER D FORMAN SJ NILAND J NUNEZ R DOMANSKI PI COLAMONICI O
Citation: R. Spielberger et al., PILOT-STUDY OF INTERFERON-ALPHA RECEPTOR (IFN-ALPHA-R) EXPRESSION IN PATIENTS WITH CHRONIC MYELOGENOUS LEUKEMIA (CML), Blood, 86(10), 1995, pp. 2100-2100
INCREASED INCIDENCE OF 2ND NEOPLASMS IN PATIENTS TREATED WITH INTERFERON-ALPHA-2B FOR HAIRY-CELL LEUKEMIA - A CLINICOPATHOLOGICAL ASSESSMENT
Authors: KAMPMEIER P SPIELBERGER R DICKSTEIN J MICK R GOLOMB H VARDIMAN JW
Citation: P. Kampmeier et al., INCREASED INCIDENCE OF 2ND NEOPLASMS IN PATIENTS TREATED WITH INTERFERON-ALPHA-2B FOR HAIRY-CELL LEUKEMIA - A CLINICOPATHOLOGICAL ASSESSMENT, Blood, 83(10), 1994, pp. 2931-2938
PRIMARY LYMPHOMA OF THE LIVER - REPORT OF A CASE WITH DIAGNOSIS BY FINE-NEEDLE ASPIRATION
Authors: NETTO D SPIELBERGER R AWASTHI S BALABAN EP NOWAK JA DEMIAN SDE
Citation: D. Netto et al., PRIMARY LYMPHOMA OF THE LIVER - REPORT OF A CASE WITH DIAGNOSIS BY FINE-NEEDLE ASPIRATION, Acta cytologica, 37(4), 1993, pp. 515-519
Risultati: 1-18 |